Welcome to our dedicated page for Aurora Spine news (Ticker: ASAPF), a resource for investors and traders seeking the latest updates and insights on Aurora Spine stock.
Aurora Spine Corporation develops and manufactures minimally invasive spinal implants and interventional pain management technologies for spinal surgery. News about ASAPF commonly covers product launches, patent issuances and commercialization updates across the company's spine portfolio, including DEXA Technology bone density-matched implants, ZIP implants, SiLO systems, Hydra A.E.R.O. facet fusion products and Aurora Biologics.
Recurring updates also include financial results, sales-force and product-adoption commentary, medical meeting participation and intellectual-property expansion through U.S. patents. Company releases emphasize implant designs that match patient bone density, fusion and motion-preservation applications, and integrated biologic support for spinal fusion procedures.
Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has announced key leadership promotions, elevating Matt Paxton to Executive Vice President of Sales and Katelyn Sims to Area Vice President of Commercialization and Key Accounts.
As Executive Vice President of Sales, Paxton will lead company-wide initiatives focusing on operational excellence and strategic growth. Sims, in her new role as Area Vice President of Commercialization and Key Accounts, will oversee sales and market strategies implementation to expand the reach of Aurora Spine's products.
Matthew Goldstone, Chief Commercialization Officer, emphasized that these promotions align with Aurora Spine's 2025 goals and reflect the company's commitment to developing internal talent. The company, which designs and manufactures innovative medical devices for spinal surgery, aims to continue its focus on simplifying complex spinal procedures and delivering superior patient outcomes.
Aurora Spine (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices for spinal surgery, has announced a conference call to discuss its third quarter fiscal 2024 financial results for the period ended September 30, 2024. The conference call is scheduled for Monday, October 28, 2024, at 11:00 a.m. Eastern Time. Investors can join via phone or webcast, with replay options available until November 4, 2024.
Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has launched its new OSTEO ONYX™ lumbar fusion system, featuring Rough Surface Technology (RST). This innovative system is designed to accommodate both standard spine patients and those with challenging conditions such as osteopenia or osteoporosis.
Ron Eckels, US Director of Spine at Aurora Spine, highlighted the system's versatility in treating a wide range of patients. Dr. Daniel Barba of San Diego, CA, was the first surgeon to use the Hydra Osteo Onyx MIS System in the United States. He praised the roughened surface technology for providing excellent purchase within the pedicle, benefiting patients with osteoporosis or poor bone quality. Dr. Barba also noted that the range of MIS screws (4.5mm to 10.5mm) allows for minimally invasive procedures, leading to improved patient recovery and satisfaction.
Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has announced its participation in the 2024 North American Spine Society (NASS) Annual Meeting from September 25-28, 2024, at McCormick Place, Chicago. The company will showcase its latest innovations at Booth #4510, including:
- SiLO™ TFX SI Fusion System for sacroiliac joint fusion surgery
- DEXA-C cervical interbody cage system with patented DEXA™ Technology
- Hydra™ and OSTEO-ONYX™ lumbar fusion systems with Rough Surface Technology (RST)
- ZIP-51® Interlaminar Fusion System for minimally invasive L5/S1 fusion
Aurora Spine's executives emphasize the transformative nature of their products, particularly highlighting the DEXA-C implant line as the world's first patient-matched interbody implant system.
Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) announces a recorded ZOOM call on September 13, 2024, featuring CEO Trent Northcutt and Alpha Wolf Trading CEO Tim Weintraut. The call will highlight Aurora's latest innovations and financial success, including:
1. DEXA™ Technology: Patient-specific interbody implants
2. New Product Launches: Hydra and Osteo-Onyx Lumbar Screw Systems
3. ZIP™ Multi-Center Study Results
4. SiLO™ TFX SI Joint Fusion System: Fastest-growing product
Financial highlights include:
- Q2 2024 EBITDAC: $105,522
- Q2 2024 sales: $4,079,543 (14.3% increase)
- Q2 gross margin: 62.4%
- SiLO™ sales: $1.7 million (41.7% of Q2 revenue)
- ZIP™ 51 sales doubled to $669,316
Aurora continues to expand its sales force and host advanced training sessions for physicians.
Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has announced its participation in the Latin America Pain Society (LAPS) Annual Congress from September 5-7, 2024, in Mexico City. The company, which specializes in designing and manufacturing innovative medical devices for spinal surgery, will showcase its latest advancements in minimally invasive spinal devices and pain management solutions.
The LAPS conference provides Aurora Spine with a platform to present technologies aimed at optimizing patient care, reducing recovery times, and improving quality of life. The event brings together nationally and internationally renowned experts in pain management, offering opportunities for knowledge sharing and peer interaction. Matt Goldstone, Chief Commercial Officer of Aurora Spine, expressed excitement about participating in the conference and showcasing the company's cutting-edge advances and state-of-the-art technologies for better patient care.
Aurora Spine (OTCQB: ASAPF), a developer of innovative spinal surgery devices, will participate in the Sixth Annual American Society of Pain & Neuroscience (ASPN) Conference from July 11-14, 2024, in Miami Beach, Florida. Aurora will showcase its products at Booth 121 and host a product theater on July 12th at 10:15 a.m.
During the event, prominent physicians Dr. Pankaj Mehta, Dr. Steven Falowski, and Dr. Jason Pope will present findings from Aurora Spine’s Refine Study. This study is the first multi-center, multi-specialty, randomized control trial focusing on interlaminar fusion, comparing Aurora’s SILO TFX and ZIP 51 devices. Aurora's President and CEO, Trent Northcutt, expressed enthusiasm for the opportunity to present their cutting-edge products and clinical results to leading physicians.
Aurora Spine has scheduled a conference call to update investors and discuss its first quarter fiscal 2024 financial results. The call will take place on May 14, 2024, at 11:00 a.m. Eastern Time. Interested parties can access the call via dial-in or webcast. A replay will be available for a time.
Summary not available.
Summary not available.